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ABSTRACT 
Disability associated with chronic pain is a prevalent worldwide problem. Much of our 
understanding of how and why chronic pain develops has been provided through 
developments in neural imaging and assessment techniques. Such investigations have 
highlighted the substantial amount of neural plasticity, or neural reorganisation, that is 
possible within the nociceptive system. While this plasticity is often physiologically 
beneficial and usually reverses over time, persistent plasticity can occur following long term 
activation or damage to the nociceptive system. These adaptations are associated with the 
development and maintenance of chronic pain conditions. This review provides an outline 
of the nociceptive system and describes the evidence for plasticity of the system at 
peripheral, spinal, and supraspinal levels. A number of clinical symptoms associated with 
chronic pain are described along with the possible neural mechanisms that may contribute 
to the presentation. Finally, chronic pain management approaches that promote 
reorganisation of the nociceptive system are discussed. These include sensory training, non-
invasive brain stimulation, and mechanisms-based treatment. 
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I. INTRODUCTION 
Chronic pain is defined by the International Association for the Study of Pain (IASP) as pain 
persisting for more than 3 months, or beyond the expected time of tissue healing.1 
Worldwide, chronic pain has a prevalence of approximately 15-20% of the adult 
population.2-5 It is therefore one of the most disabling chronic conditions, yet it suffers from 
a distinct lack of identity, recognition, and acceptance. Pain is so often viewed as a symptom 
of another condition, e.g. arthritis or spinal cord injury, that the neural changes that occur 
with long term pain are rarely acknowledged. Part of the problem contributing to the 
limited recognition of chronic pain is that pain is a purely subjective experience and there 
are no valid physical tests that can be used for diagnosis. It is also complicated in that pain is 
multidimensional, being both a sensory and emotional experience, and is commonly 
associated with adaptations in other areas of the nervous system, including somatosensory, 
motor, autonomic, and cognitive functions. However, chronic pain is now receiving 
recognition as its own disease entity, and with advances in neural imaging and assessment 
techniques, greater insight has been provided on the plasticity that occurs within the 
nervous system in long term pain conditions. This paper will highlight evidence of this neural 
plasticity and attempt to link it to the common symptoms present in chronic pain. 
II. OVERVIEW OF THE NOCICEPTIVE SYSTEM 
To more fully understand the neuroplastic changes in the nociceptive system associated 
with long-term pain, an overview of the system is presented first. There are a wealth of 
textbooks and review articles that provide this information in detail,6-9 so a brief and simple 
version is presented here. Receptors that are sensitive to noxious stimuli (nociceptors) are 
present in most tissues of the body. These nociceptors are free nerve endings that respond 
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to harmful or potentially harmful chemical, mechanical, and thermal stimuli and relay this 
information via Aδ and C fibre axons (also termed group III and IV fibres, respectively) to the 
dorsal horn of the spinal cord. Aδ fibres are lightly myelinated and relatively fast conducting, 
while C fibres are non-myelinated and have a small axon diameter, making them the slowest 
conducting of our sensory afferents. In the dorsal horn, nociceptive afferents predominantly 
synapse with onto second order neurons in superficial laminae I and II as well as deeper into 
laminae IV-VI. Second order neurons in laminae I and II are primarily nociceptive specific 
neurons that only receive input from Aδ and C fibres. In lamina IV-VI, nociceptors synapse 
with wide dynamic range (WDR) second order neurons that receive input from multiple 
afferents. WDR neurons are principally located in laminae IV-VI but can also be found in 
laminae I and II. In comparison to Aδ and C fibres, axons from non-noxious touch and 
proprioceptive receptors, known as Aβ fibres, synapse in the deeper laminae III-V only.  
Nociceptors predominantly communicate using the neurotransmitters glutamate, an amino 
acid, and substance P, a slow-acting neuropeptide. In normal conditions, glutamate binds to 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors on the dorsal horn 
cells and causes a short acting excitatory potential. Substance P binds to the neurokinin-1 
receptor, a G-protein couple receptor, to generate a much slower and longer acting 
depolarisation. Glutamate may also bind to N-methyl-d-aspartate (NMDA) receptors but at 
resting membrane potential the NMDA receptors are blocked by the ion Mg2+. Dorsal horn 
neurons themselves are connected both within the same spinal cord layer through 
interneurons that traverse laminae, and within close spinal segments through ascending and 
descending propriospinal interneurons.  
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From the dorsal horn, nociceptive information ascends to brainstem and cortical regions in 
medial and lateral pathways. Key areas in the brainstem that receive direct nociceptive 
input are the midbrain periaqueductal grey (PAG), the rostral ventromedial medulla (RVM), 
and the reticular formation. These areas have notable roles in the modulation of the 
ascending nociceptive signal. Cortical and subcortical regions receiving direct nociceptive 
input reflect a highly connected network of sites involved in the perception, interpretation, 
and behavioural response to nociceptive input. These areas include the thalamus, primary 
and secondary somatosensory cortices, anterior cingulate cortex, amygdala, prefrontal 
cortex, and the insula, and are collectively referred to as the neuromatrix. It is when 
nociceptive information arrives in the neuromatrix that the lived experience of pain is 
created, with the lateral system providing the sensory-discriminative component of pain and 
the medial system contributing to the emotional-aversive component. The neuromatrix 
itself has bilateral projections to brainstem modulatory areas, providing a means for 
cognitive and emotional modulation of the ascending nociceptive signal. The hypothalamus 
is also intimately connected with neuromatrix and brainstem regions, facilitating interaction 
between the autonomic and nociceptive components of the nervous systems. 
Modulation of the ascending nociceptive signals can be both facilitatory and inhibitory and 
occurs at multiple levels of the nociceptive system. Descending excitatory and inhibitory 
modulatory pathways are tonically active, with the extent of activation influenced by 
nociceptive input, psychological stress, or other forms of nervous system stimulation. Shifts 
in the balance of inhibitory and excitatory activation therefore determine the overall 
modulation of nociceptive signals. In the periphery, nociceptive signals can be facilitated 
through sensitisation of nociceptors that occurs following tissue injury and inflammation, 
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while activation of non-noxious mechanoreceptors can activate the dorsal horn spinal gating 
mechanism and reduce nociceptive input. Within the dorsal horn, a multitude of inhibitory 
and excitatory interneurons serve to modulate the transmission from nociceptors to 
ascending pathways. GABAergic inhibitory interneurons play a particularly important role at 
this level in reducing the ascending signal. In key modulatory regions of the brainstem, 
including the RVM and PAG, there are classes of neurons termed ON and OFF cells. These 
cells activate descending facilitatory and inhibitory pathways, respectively, that act directly 
or indirectly on dorsal horn neurons. Two of the main neurotransmitters associated with 
inhibitory pathways are serotonin, released following activation of the raphe magnus 
nucleus, and noradrenaline, released following activation of the locus ceruleus. A further, 
well established inhibitory system involves the activation of diffuse noxious inhibitory 
control neurons located in the caudal medulla. At a cortical level, the strong bi-directional 
interaction with brainstem centres affords a means for cognitive and emotional factors to 
modulate the nociceptive signal. These include psychological factors such as attention, 
expectations, mood, arousal, and beliefs regarding pain. Finally, the hormonal system 
provides an additional important source of nociceptive modulation. Circulating endogenous 
opioids can act to inhibit the nociceptive signal through receptor activation at peripheral 
nociceptors, spinal cord dorsal horn, brainstem, and cortical sites. Importantly, opioid 
receptor density and distribution is dynamic and is regulated by activation of the 
nociceptive system, nerve and tissue damage, and the peptide hormone cholecystokinin 
(CCK). 
It is apparent that the nociceptive system is a multi-faceted and dynamic network that 
affords enormous capacity for short- and long-term plasticity. Nociception facilitation and 
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inhibition is normally regulated physiologically to provide a useful response that at first 
alerts us to actual or potential tissue damage, promotes recovery and restoration, and then 
enables increasing use and activity as the body recovers. Thus, the pain experience is 
temporally matched to tissue damage and repair. When this process escapes tight 
regulation and pain continues far beyond the period of tissue recovery, the consequences 
can be catastrophic for an individual. It is indeed not surprising that chronic pain is 
commonly associated with depression, anxiety, reduced participation, and impaired quality 
of life.2,10-12 There is increasing evidence that this dysregulated response of the nociceptive 
system arises through persistent plasticity. The following sections of this review will 
examine in more depth the neural changes that have been identified in the nociceptive 
system following tissue damage and how these may underlie the common clinical features 
of chronic pain conditions. 
III. PLASTICITY IN THE NOCICEPTIVE SYSTEM 
There are many mechanisms that can underlie neural plasticity and many levels within the 
nociceptive system at which plasticity can occur. In general, the adaptive responses to acute, 
nociceptive pain are physiologically useful and predominantly serve to augment the 
ascending nociceptive signal to promote awareness of tissue injury and recuperative 
behaviour. However, much of the reorganisation that occurs with chronic pain appears to 
serve no biological purpose, and may even be profoundly detrimental, contributing to the 
maintenance of pain. The following provides a description of potential neural plasticity at 
each level of the nociceptive system. 
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A. Peripheral nociceptors 
Tissue damage or inflammation and the subsequent activation of nociceptors result in 
almost immediate changes in peripheral nociceptive system function. A soup of chemical 
mediators, including inflammatory substances, catecholamines, and neuropeptides are 
released locally. These substances can directly activate free nerve endings and rapidly 
increase their excitability, a process termed peripheral sensitisation. Peripheral sensitisation 
is characterised by a reduction in nociceptor activation threshold and the development of 
spontaneous nociceptor discharge, leading to an increased nociceptor response to a given 
noxious stimulus. Nerve growth factor is a particularly important sensitising agent that is 
implicated in the development of longer-term neuronal changes.13 Nociceptors themselves 
play a contributory role in peripheral sensitisation through the antidromic propagation of 
action potentials and subsequent release of substance P and calcitonin gene related peptide 
(CGRP) from their sensory terminals into the peripheral tissue.14 These substances cause 
enhanced vascular permeability, vasodilation, and increased synthesis of prostaglandins, 
further enhancing nociceptor activation and sensitisation. As well as these effects on 
functioning nociceptors, a group of nociceptors that are normally dormant, termed silent 
nociceptors, become activated during inflammation and sensitisation.15 These newly 
awakened receptors respond intensely to both noxious and non-noxious stimuli, increasing 
the peripheral afferent barrage into the spinal cord. Additionally, glial cells (microglia and 
astrocytes), long thought to play a strictly structural role in the nervous system, are now 
known to contribute to peripheral sensitisation. Glia are activated by pathogens and 
inflammation and release pro-inflammatory cytokines that further facilitate nociceptor 
sensitisation.16 Emerging evidence from animal studies suggests that peripheral sensitisation 
can cause nociceptors to respond more vigorously the next time they are exposed to 
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inflammatory mediators, a phenomenon termed “hyperalgesic priming”.17 In their primed 
state, the resulting sensitisation of nociceptors is much stronger and longer lasting when 
exposed to a second dose of inflammatory mediators. The length of time the exposed 
nociceptors remain in this primed state is unknown but appears to be at least a few weeks 
after the initial inflammatory response.17       
Nociceptor axons that are damaged through demyelination or a lesion can fire 
spontaneously, sending a constant volley of signals to the dorsal horn. Termed ectopic 
discharge, the spontaneous activation can begin early following nerve damage, can be 
rhythmic or irregular depending on the fibres involved,18 and appears to arise through 
upregulation and altered trafficking of Na+ channel expression.19 Damaged axons are 
particularly sensitive to circulating catecholamines,20,21 which can lead to further axonal 
firing. Traumatic axonal damage commonly results in the formation of neuroma, or an 
accumulation of nerve tissue. Neuroma themselves facilitate spontaneous firing of action 
potentials due to the accumulation of Na+ channels.22 Nerve injury also causes the 
expression of novel receptors in the neuroma that are sensitive to inflammatory chemicals,6 
adding to the spontaneous axonal firing. Ectopic discharge from axons or neuroma can 
continue for lengthy periods of time, providing a continuous input to second order neurons 
within the spinal cord.  
Damage or demyelination of multiple axon types also can lead to ephaptic discharge. In this 
case, afferent signals jump across axons in areas of damage. Thus, ephaptic transfer may 
lead to an action potential along an Aβ fibre transferring to a neighbouring nociceptor axon 
and subsequently ascending to the cortex in normally nociceptor-specific pathways.23 
Additionally, a phenotypic switch in non-noxious Aβ fibres to release substance P has been 
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documented following nerve damage or inflammation.24,25 This enables non-noxious stimuli 
to activate dorsal horn neurons that are usually responsive to noxious input only. 
B. Spinal Cord Dorsal Horn 
Prolonged nociceptive input, particularly from deep tissue afferents, instigates additional 
neuroplastic changes within the spinal cord dorsal horn. The release of the slow-acting 
neurotransmitter substance P causes sustained depolarisation of dorsal horn neurons, 
instigating changes in neurotransmitter receptor availability. Depolarisation of second order 
neurons stimulates the removal of the Mg2+ block from NMDA receptors, making them 
available for glutamate binding.26 Activation of pre- and post-synaptic NMDA receptors in 
the dorsal horn causes a large and prolonged depolarisation, increased intracellular Ca2+ 
influx, and can stimulate the additional release of neuropeptides, such as substance P.27-29 
NMDA receptor activation also enables the phenomenon of windup to occur in WDR 
neurons. Windup is instigated by temporal summation of high frequency (>0.3 Hz) 
nociceptive input that gives rise to a progressively increased depolarisation of WDR 
neurons.26,30 This process results in an increase in firing frequency of the second order 
neurons. In addition, sustained depolarisation leads to an expansion of the receptive zone of 
WDR neurons,31 may cause new receptive fields to be established,32 and increases the 
sensitivity of WDR neurons to both noxious and non-noxious inputs.31 These are the first 
and fundamental steps of central sensitisation. The overall effect is an increased number of 
action potentials generated in nociceptive pathways ascending to neuromatrix regions.  
Glial cells, substance P, and the enzyme cyclo-oxygenase-2 (COX-2) also play a role in 
facilitating nociceptive transmission at the dorsal horn and a spread from local to more 
diffuse effects. Glial cells are incredibly well interconnected and communicate via gap 
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junctions, facilitating a rapid spread of activation. Activated glial cells facilitate the release of 
substance P from nociceptors16 and pro-inflammatory cytokines,33 increasing depolarisation 
of second order neurons and enhancing COX-2 expression in the dorsal horn. The extended 
release and slow re-uptake properties of substance P enable the peptide to diffuse to 
adjacent synapses or even across the dorsal horn,34 contributing to the sensitisation of 
second order neurons in remote areas. The enzyme COX-2 is used in the synthesis of 
prostaglandins from arachidonic acid. COX-2 that is produced in the dorsal horn does not 
remain local but travels through the spinal cord and to supraspinal regions.35 This can lead 
to increased prostaglandin production in cerebrospinal fluid and widespread facilitation of 
dorsal horn sensitisation.  
Further, longer lasting changes in the dorsal horn occur with prolonged stimulation. 
Sustained activation of nociceptors or nerve damage causes upregulation of c-fos, an 
immediate early gene and a marker of neuronal activity. Several seconds of activation is 
enough to induce transient labelling in superficial laminae of the dorsal horn, while 4-5 
hours of stimulation can lead to labelling in deeper laminae.36 Such activation can cause 
alterations in the expression of neurotransmitters, receptor availability, ion channel 
function and numbers, and even structural reorganisation. Following inflammation or nerve 
damage, there is an increase in receptor availability for glutamate and substance P in dorsal 
horn cells37 and enhanced release of these neurotransmitters.29 There are also alterations 
associated with inhibitory pathways. Changes in the opioid system at the dorsal horn 
include a reduction in opioid receptor numbers,38 up-regulation of opioid receptor 
antagonists,39 and increased CCK release that reduces the ability of morphine to bind to 
receptors.40 There also may be loss of inhibitory glycine receptors,41 depression of gamma-
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aminobutyric acid (GABA) inhibitory interneurons,42 or even a functional switch of GABA-
mediated synapses from inhibitory to excitatory.43  
Peripheral nerve damage may also lead to alterations in neuronal firing properties and 
dorsal horn connectivity. Dorsal horn neurons can alter from a tonic firing pattern to the 
formation of plateau potentials,44 which enhances and amplifies signal transmission. Glia 
present in the dorsal horn can be upregulated following nerve damage,45 reinforcing their 
sensitising effect on second order neurons. Interneurons present within the dorsal horn that 
connect deeper to superficial laminae are normally inactive, but following nerve injury these 
pathways may be facilitated.46 This polysynaptic pathway provides a means for non-noxious 
Aβ input into deeper laminae to indirectly activate superficial dorsal horn neurons and 
ascending nociceptive pathways. 
Structural changes around the dorsal horn can also occur. Peripheral axonal damage can 
lead to fibre death; this appears to be more predominant in non-myelinated C fibres.47 With 
the death and withdrawal of C fibres, Aβ fibres have been shown to invade the superficial 
laminae of the dorsal horn and make functional synapses with nociceptive specific 
neurons.48,49 The release of nerve growth factor in the dorsal horn can also instigate C fibre 
sprouting,50 increasing the number of functional synapses from nociceptors to second order 
neurons. Apoptosis, or death, of dorsal horn GABA inhibitory interneurons may also occur,42 
although more recent findings have challenged this assertion.51 
These factors may all contribute to central sensitisation at the spinal cord level. While acute 
central sensitisation may be useful in nociceptive pain, long-standing sensitisation of dorsal 
horn neurons is pathological. A number of the mechanisms of plasticity described above can 
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lead to sensitisation persisting after removal of incoming nociceptive stimuli, or result in 
very little input needed to sustain sensitisation.52,53 
C. Brainstem Regions 
Neuroplasticity is not limited to the dorsal horn but can continue into supraspinal regions. 
There is now good evidence of alterations in brainstem descending pain inhibitory and 
facilitatory pathways in many chronic pain populations. Although it is difficult to establish 
the chronology of such alterations, several studies have provided evidence that 
inflammation and peripheral nerve damage can give rise to subsequent changes in 
brainstem modulatory regions, suggesting a causative effect.  
After acute tissue injury or inflammation, there is net increase in both descending inhibition 
and facilitation from multiple supraspinal sites, particularly the RVM and locus ceruleus.54 As 
well as altered activity in existing ON and OFF cells, a phenotypic switch of neurons may 
occur. A third class of cells in brainstem regions, termed NEUTRAL cells, do not normally 
respond to nociceptive input. However, following activation of the nociceptive system, 
these NEUTRAL cells can be converted to ON or OFF cells, potentially mediating the 
increased descending activity.55 Although the overall modulation of ascending nociceptive 
signals is upregulated, there are distinct temporal shifts in the balance between inhibition 
and facilitation. Facilitation dominates early after injury, with inhibition taking time to 
build.56 The delayed inhibition predominates with time and likely serves as a mechanism to 
dampen dorsal horn hyperexcitability. However, in a chronic inflammatory model, it has 
recently been shown that despite descending inhibition being increased, the mechanical 
threshold for an OFF cell pause (i.e., removal of descending inhibition) is significantly 
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lowered,57 perhaps providing a basis for mechanical hypersensitivity in prolonged 
inflammatory states.  
More sustained changes in the balance of descending facilitation and inhibition occur with 
ongoing nociceptive input. Following nerve injury, there is evidence of reduced inhibition 
and increased facilitation from the medulla58,59 and death of some RVM cells may occur.60 
Additionally, the normally inhibitory locus ceruleus, which gives rise to the descending 
ceruleospinal pathway, may switch to a facilitatory input.61 Long-term exposure to 
morphine also has been shown to increase the number of ON cells in the RVM.62 Such 
changes would give rise to a shift in the balance of descending modulation towards tonic 
facilitation. In support of this, increased activity in the RVM and PAG has been documented 
in people with chronic allodynia following nerve injury63 and is associated with punctuate 
hyperalgesia in chronic hip osteoarthritis,64 suggestive of enhanced facilitation of 
nociceptive input by these supraspinal centres.  
It is also now established that several chronic pain populations have impaired conditioned 
pain modulation,65 a paradigm used to assess the function of the diffuse noxious inhibitory 
control system. Impaired inhibition by this system has been documented in people with 
arthritis,66,67 fibromyalgia,68,69 chronic headache,70-72 irritable bowel syndrome,73-75 and 
temperomandibular joint disorder.76,77 Thus, it appears to be a phenomenon that is not 
specific to any particular chronic pain pathology. Of note, there is evidence that impaired 
conditioned pain modulation can be restored with pain relief.67,78 These studies provide 
evidence that conditioned pain modulation is modifiable over time and is temporally 
associated with the pain experience. Animal models of mild or chronic stress also have 
shown that brainstem regions are involved in the development of hyperalgesia,79-81 
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providing evidence for a “top-down” modulation of plasticity in brainstem pathways by 
cortical regions.  
D. Cortical reorganisation 
Brain structural and functional imaging techniques have provided evidence of morphological, 
metabolite, and neuronal excitability changes in people with various long term pain 
conditions. Numerous magnetic resonance imaging (MRI) studies have shown atrophy of 
grey matter in neuromatrix regions. These have included populations with low back 
pain,82,83 headache,84,85 irritable bowel syndrome,86 osteoarthritis,87,88 complex regional pain 
syndrome (CRPS),89 and fibromyalgia.90 This is not a widespread phenomenon but appears 
to be a functionally specific atrophy that is regionally different among the various pain 
conditions. The chronology of such grey matter changes is difficult to determine, but a 
handful of longitudinal studies have convincingly demonstrated that changes in reported 
pain intensity over time are mirrored by alterations in structural grey matter 
volume,83,85,87,88 suggesting that the latter may be a consequence of the former. One caveat 
that should be mentioned is that most of these studies have not taken patient co-
morbidities into account and some have revealed structural changes in non-neuromatrix 
regions, so such reorganisation may not always be pain-specific.91 
Changes in concentration of specific brain metabolites have been demonstrated in 
neuromatrix regions of people with chronic low back pain,92-95 CRPS,96,97 spinal cord 
injury,98,99 and post-herpetic neuralgia.97 In fact, it was some of this early work using 
magnetic resonance spectroscopy that lead to the hypothesis that morphological changes 
may be present in the brain. These studies have predominantly reported decreased 
concentration of N-acetyl-aspartate (NAA; a marker of neuronal function) and glutamate 
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metabolites in several cortical and subcortical regions, including the primary sensorimotor 
cortex, thalamus, insula, and anterior cingulate cortex. The clinical importance of such 
findings is evident in that the concentration of metabolites related to glutamate and NAA in 
people with spinal cord injury was able to distinguish between those with pain and those 
without.98,99 Reduced concentration of these specific metabolites reflects a loss of neurons 
or neuronal dysfunction in specific neuromatrix regions. It has been speculated that this 
arises through a neurodegenerative processes due to enhanced neural activity in these 
regions in people with long-term pain.96 Of note, individuals with visceral pain who had the 
lowest baseline concentrations of glutamate and NAA showed the greatest pain reduction 
with treatment,100 suggesting that lowered concentrations of the metabolites are a marker 
of potential pain recovery. 
Furthermore, there is evidence for more specific reorganisation occurring within the 
primary somatosensory and motor cortices in chronic pain conditions. Flor and colleagues101 
were one of first to document shifts in cortical sensory representation maps of people with 
phantom limb pain. Since then, numerous studies have reported similar alterations in bodily 
representation in the somatosensory cortex of amputees with phantom limb pain102-105 that 
are not present in those without pain.105 It is possible that this plasticity reflects a 
compensatory measure to restore function in deafferented cortical regions. However, there 
are alterations in cortical representation in other chronic pain conditions that do not involve 
amputation, so this reorganisation is not entirely dependent on structural deafferentation. 
For example, in people with chronic back pain, a medial shift of the back representation 
within the somatosensory cortex has been reported without any reorganisation in other, 
non-painful body regions.106 Additionally, reduced or altered locations of primary 
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somatosensory cortex representations of the painful body region have been documented in 
studies involving people with CRPS,107-110 spinal cord injury pain,111 and those with pain 
associated with carpal tunnel syndrome.112  
There are also structural and functional changes in the primary motor cortex in populations 
with chronic pain. Shifts in motor cortical representation in people with low back pain113,114 
and phantom limb pain103,104,115 have been reported. Studies using transcranial magnetic 
stimulation to examine corticomotor excitability in chronic pain have shown altered 
responses in a number of chronic pain populations. The findings have generally indicated an 
increase in corticomotor excitability115,116 and a reduction in intracortical inhibition117-123 in 
the affected body region. These findings appear to be supported by a functional MRI (fMRI) 
study showing increased ispi- and contra-lateral primary motor cortex activation in people 
with CRPS during hand movement.124 However, some authors have reported normal121 or 
reduced corticomotor excitability122 in chronic pain populations, and it is likely that the 
outcomes are influenced by the pain condition or methodological differences among studies. 
Regardless, it seems obvious that ongoing nociceptive input influences cortical motor 
regions. The noted reduction in intracortical inhibition may be particularly important given 
the role of these circuits in cortical plasticity.125  
In addition to these morphological and neural excitability changes, there is evidence of 
adaptations in white matter tracts, glia concentration, and cortical opioid binding potential 
in those with chronic pain. Regional white matter abnormalities, reflecting plasticity of 
connectivity between neuromatrix regions, have recently been shown in people with 
CRPS,89 irritable bowel syndrome,126 spinal cord injury pain,127 and chronic back pain.94 
Similar to the alterations in grey matter, the white matter alterations appear to reflect 
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anatomically specific adaptations rather than a global reduction or increase in connectivity. 
Other studies have shown reduced opioid binding potential in several cortical neuromatrix 
regions. These have included people with fibromyalgia,128 rheumatoid arthritis,129 and 
stroke,130 although the precise locations involved appear to differ among population groups. 
These studies raise the possibility that chronic activation of receptors by endogenous 
opioids in long-term pain conditions leads to a down regulation of receptor availability. 
Finally, a recent magnetic resonance spectroscopy study showed greater concentration of 
metabolites related to glial markers in the anterior cingulate cortex of people with severe 
neuropathic pain following spinal cord injury.99 This alteration was not present in those with 
spinal cord injury without pain or with less severe pain, and provides evidence that 
proliferation of glia and glial activation within the cortex may contribute to the maintenance 
of neuropathic pain. 
E. Summary 
These examples of plasticity show the many levels within the nociceptive system that can 
adapt in response to ongoing stimulation of the system. The time-course of these events 
can be remarkably rapid. Windup of dorsal horn neurons takes less than 100 ms to manifest, 
changes in receptor availability and receptive zones can occur within minutes, programmed 
cell death and unmasking of latent connections may be evident within hours, while dorsal 
horn sprouting and other anatomical changes can arise in days.7 Chronic inputs can serve to 
reinforce this plasticity, contributing to an ongoing cycle of pain and adaptation. Importantly, 
such adaptation should not be looked at in isolation. Plasticity in the periphery, dorsal horn, 
supraspinal regions, and in glia is inter-related and reflects the complexity and marked 
interaction of the nociceptive system across many levels. 
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IV. CLINICAL PRESENTATIONS OF NEURAL PLASTICITY IN CHRONIC PAIN 
Classic findings in people with chronic pain are an increased response to noxious stimuli at 
the site of injury (primary hyperalgesia) and at neighbouring regions (secondary 
hyperalgesia), a pain response to harmless stimuli that would not normally be painful 
(allodynia), and the presence of spontaneous innocuous (parathesia) and unpleasant 
(dysesthesia) sensations. Disturbances in additional sensory and perceptual systems as well 
as motor symptoms are also common presentations in chronic pain. The following section 
presents some of the possible underlying neural mechanisms associated with these signs 
and symptoms based on the descriptions of plasticity provided above.  
A. Spontaneous pain and phantom pain 
Spontaneous pain is common following nerve damage and is commonly described as 
shooting, burning, or stabbing sensations. Ectopic discharge from damaged neurons or 
neuromata provide a source of nociceptive input to the spinal cord dorsal horn. If this input 
is sufficient to activate second order neurons, an ascending signal will be sent to the 
neuromatrix and may lead to pain being experienced. Spontaneous pain arising solely from 
ectopic discharge can be blocked by anaesthesia of the nerve, so it is relatively simple to 
determine if this is the sole contributor to spontaneous pain sensations. Since sympathetic 
discharge and circulating catecholamines can facilitate ectopic discharge from damaged 
axons or neuromata, people with chronic pain may report greater spontaneous pain 
sensations when under emotional stress. 
Cortical plasticity may also underlie spontaneous and phantom pain. Reorganisation within 
the primary somatosensory101,102,131 and motor103,104 cortices has been associated with the 
magnitude of reported phantom limb pain. While some report that these representational 
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shifts are not present in congenital amputation or those without phantom limb pain,102 
others have provided evidence of reorganisation in amputees who do not experience 
pain.132 It is known that deafferentation or amputation itself can lead to sensory and motor 
cortical plasticity.132,133 Thus, alterations in cortical sensory and motor map representations 
do not necessarily give rise to phantom pain in amputees, but may contribute to its 
maintenance. People with phantom limb pain appear to have disordered motor control of 
the phantom limb compared to those without pain, and it is speculated that an inability to 
move the phantom limb and generate afferent feedback to the sensory cortex may 
contribute to this pain.134 
B. Allodynia 
Allodynia is the perception of pain in response to a non-noxious stimulus. It is commonly 
assessed using brush, touch, thermal, or vibration stimuli and is a frequent symptom in 
chronic pain conditions such as CRPS135 and whiplash.136,137 According to international 
criteria, the term allodynia must only be used when it is certain that the stimulus does not 
activate nociceptors, and therefore it is primarily associated with Aβ fibre activation. 
Evidence for the involvement of Aβ fibres is provided by the rapid activation of cortical 
regions following application of allodynic stimuli, which is consistent with involvement of 
fast conducting axons.138 
Allodynia can arise through several of the mechanisms described in the preceding section. 
This includes sensitisation of WDR neurons and subsequent increased responsiveness to 
non-noxious input, ephaptic discharge between Aβ and nociceptive fibres, invasion of Aβ 
fibres into the superficial laminae of the dorsal horn, activation of latent interneurons from 
deep to superficial dorsal horn laminae, and release of substance P by Aβ fibres. While 
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evidence for the occurrence of these processes is difficult to provide in man, there is 
substantial evidence of such plasticity in animal work described in the preceding section.  
In humans, cortical imaging studies have perhaps provided the best evidence of altered 
neural processing in allodynia. Several studies undertaken with neuropathic pain patients 
have shown cortical activation networks in allodynia that are different from that seen during 
the presentation of equivalent, non-painful stimuli or during nociceptive pain.139-142 
Maihöfner and colleagues143 also have shown altered neuromatrix activation during skin 
brushing in healthy people who have been given experimentally induced allodynia. Thus, the 
experience of allodynia clearly arises through altered processing of non-noxious input. 
While not all of the clinical studies elicited common activation networks, in general there is 
evidence of a larger extent of cortical activation during allodynia and a shift to more lateral 
or sensory-dominant neuromatrix regions. 
C. Hyperalgesia 
Consistently, people with chronic pain have reduced pain thresholds, or, for a given 
intensity of noxious stimulation, will report a higher pain rating. Localised reductions in 
threshold that are specific to the area of tissue injury or pathology are common. For 
example, significantly reduced pain thresholds in local pain areas have been reported in 
fibromyalgia,144,145 whiplash,146,147 visceral pain syndromes,75,148 low back pain,149 arthritis,66 
and headache.150 This hyperalgesia could reflect peripheral sensitisation of the nociceptors, 
localised central sensitisation within the dorsal horn, or sensitisation of cortical regions.  
The clinical detection and differentiation of peripheral and central sensitisation can be 
challenging, but surprisingly detailed conclusions can be made on the basis of routine 
sensory examinations and slightly more sophisticated quantitative sensory testing 
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procedures. Evidence that the threshold for eliciting the lower limb nociceptive flexion 
reflex is reduced in people with chronic whiplash and fibromyalgia151 shows that there is a 
definite spinal level adaptation in these conditions as the flexion reflex is not dependent on 
subjective pain report. If reductions in pain threshold can be ameliorated or eliminated by 
local anaesthesia, then it is likely that sensitisation is at least partly mediated by a short-
term mechanism that is sustained by peripheral nociceptive. If sensitisation or hyperalgesia 
is not abolished through peripheral analgesia, it is indicative of central structural alterations 
or changes in neurotransmitter or receptor types. Sprouting of nociceptor terminals, 
opening of dorsal horn latent connections, reduced glycinergic or GABAergic inhibition of 
second order dorsal horn neurons, switches from inhibitory to excitatory transmission, shifts 
in the balance of descending regulation, and reduced responsiveness to endogenous opioids 
can all contribute to central sensitisation and localised hyperalgesia.  
There is also evidence of cortical plasticity associated with hyperalgesia. The intensity of 
current or ongoing pain has been correlated with primary somatosensory cortex 
reorganisation in CRPS,107,110 spinal cord injury,111 and phantom limb pain.152 Others have 
reported that cortical metabolite concentrations98,99 and the extent of atrophy of the 
insula89 correlate with pain intensity. Stronger evidence of a relationship between pain and 
cortical plasticity has been shown in a few longitudinal studies. Functional connectivity 
involving the primary sensorimotor cortex was modulated in healthy individuals during 
sustained (6 minutes) experimental pain, with a shift towards a salience network evident.153 
Additionally, Birbaumer and colleagues105 found that an anaesthetic block both reduced the 
extent of phantom limb pain and gave rise to a normalisation of primary somatosensory 
cortex representation in amputees. The somatosensory cortex was unchanged in those who 
23 
 
did not experience analgesia. Reorganisation within the primary somatosensory cortex also 
has shown to be reversed in people with CRPS coincident with clinical improvement,109 
while brain metabolite concentrations of glutamate and NAA increased with treatment in 
people with visceral pain.100 In the latter study, the reduction in clinical pain correlated with 
changes in metabolite concentration. Thus, it is likely that these cortical adaptations reflect 
neural plasticity in response to the ongoing nociceptive signals, but they may serve to 
maintain or facilitate pain over time. 
The knowledge that a history of pain,154-156 multiple sites of pain,157-159 and prior trauma160 
are predictors of the development and impact of chronic pain following injury suggests that 
some individuals may be more susceptible to central sensitisation and hyperalgesia. Their 
baseline nociceptive system is likely to be in a state that is more likely to lead to persistent 
plasticity and transform an innocuous event into a chronic problem.  
D. Windup 
Windup is an exaggerated pain response following repeated, high frequency nociceptor 
activation. It is evident clinically as rapidly increasing pain during application of repetitive 
noxious stimuli and serves as a biomarker of central sensitisation. High frequency 
nociceptive input induces temporal summation in WDR dorsal horn neurons, the perceptual 
correlate of windup, and the presence of an exaggerated response indicates that 
sensitisation of the WDR neurons has taken place. Indeed, the temporal summation 
response is a more sensitive indicator of central sensitisation than the response to a single 
noxious stimulus.66,144  
Evidence of a relationship between peripheral tissue damage and an enhanced windup 
response is provided by a study that induced delayed onset muscle soreness in healthy 
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individuals.161 Following the induction of muscle soreness, temporal summation threshold 
was significantly reduced in the painful muscle. This suggests that sensitisation of WDR 
neurons contributed to the induced muscle hyperalgesia. Clinically, enhanced susceptibility 
to temporal summation means that persistent, minor nociceptive input from the periphery 
can lead to the perception of pain when it would normally remain subthreshold. The 
relevance of windup and temporal summation for chronic pain conditions is further evident 
in that the duration of pain symptoms has been correlated with temporal summation 
threshold in people with osteoarthritis.66  
E. Referred sensations  
Referred sensations are those that arise from areas distant to a primary location receiving 
noxious stimulation. Referred sensations are commonly reported in people with CRPS,135,162 
phantom limb pain,102,163 facial pain,163 whiplash,164 spinal cord injury,165 and 
fibromyalgia.166 During experimentally induced pain in healthy volunteers, referred pain is 
usually felt distal to the primary site, but it is often reported to spread proximally in some 
people with chronic pain. The referred sensations can match the modality of the primary 
stimulation but also may be different and can be both painful and non-painful.152 Referred 
sensations are normally present with a slight time delay (20-40 s) from the primary 
stimulation.167 
Referred sensations have been reported to be more common in people with complete 
spinal cord injury with neuropathic pain compared to those without pain165 and in amputees 
with phantom limb pain compared to those without.102 Because of this association with 
neuropathic pain, it is likely that referred sensations are related to neural plasticity. A 
possible mechanism of referred sensation is the spatial summation of noxious afferents 
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from the primary source and non-noxious afferents from the referred area.168 The use of 
anaesthetic blocks has shown that input from the primary source of pain is required for 
referred sensations to be felt.169 While some studies have shown that referred muscle pain 
persists after anaesthetising peripheral nerves innervating the referred area,170 others have 
shown a reduction in pain intensity when large afferents are blocked.168,171 This suggests 
that afferent input from the referred area is not necessary for referred sensations to 
develop but may serve to enhance those that are experienced. Since ongoing stimulation is 
required to elicit referred sensations in healthy people and there is a time delay between 
the primary and referred sensation, it is probable that central sensitisation of dorsal horn 
neurons is required. A sensitised dorsal horn may open the normally latent connections 
from nociceptors mediating pain from the primary area, activating secondary neurons that 
normally receive input from the referred pain area.164 
Interestingly, the number or extent of referred sensations elicited by painful stimuli has 
been correlated with the extent of primary somatosensory cortex reorganisation in people 
with phantom limb pain,131,152,172 suggesting a possible cortical contribution. Referred 
sensations from non-noxious stimuli were also present in the same individuals and have 
previously been reported in people with subcortical stroke who do not have ongoing pain;173 
however, the extent of cortical reorganisation was only correlated with sensations arising 
from painful stimuli.131,152,172 Therefore, while referred sensations from non-noxious stimuli 
may be a manifestation of more general cortical sensorimotor reorganisation, there appears 
to be a relationship between primary somatosensory cortex plasticity, nociceptive 
processing, and referred pain.  
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F. Widespread pain 
Many studies in people with regional chronic pain conditions have shown that pain 
thresholds are also reduced at remote, non-painful body regions.66,67,78,137,174-178 Widespread 
hyperalgesia is more severe when present across a number of stimulus modalities and 
locations,179 in people with longer term duration of pain,174,178 and in people with more 
intense pain.66,78,180,181 This widespread hyperalgesia cannot be accounted for by peripheral 
sensitisation as there is no damage or inflammation at the local site; therefore, it must be 
due to hypersensitivity in the central nervous system.  
A potential mechanism of this diffuse central sensitisation is the activation of 
intersegmental propriospinal interneurons that provide a link between second order 
neurons in the dorsal horn. An intersegmental mechanism is favoured as the spread of 
hyperalgesia does not follow dermatomal patterns. Indirect evidence of this has been 
provided by several studies examining the spread of experimentally-induced pain in chronic 
pain populations. Following the injection of hypertonic saline into specific muscles, a diffuse 
spread of pain has been reported in people with osteoarthritis,166,182 fibromyalgia,183 
whiplash,184 and chronic low back pain.149 Compared to healthy controls, the spread of pain 
was greater, lasted longer, and was more intense in the chronic pain populations. In some 
cases, pain spread to other segments of the limb or to the contralateral side. The fact that 
ketamine, an NMDA receptor antagonist, can block the spread of pain185 also points to a 
central sensitisation process involving a change in glutamate receptor availability in the 
dorsal horn. The substantial evidence that people with a longer duration of pain and more 
intense current pain are more likely to show widespread pain suggests it may take some 
time for sensitisation to spread. Ongoing peripheral input is likely to drive this plasticity at 
central regions. Indeed, evidence for the reversibility of widespread sensitisation with 
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changes in nociceptor input has been provided by Graven-Nielsen and colleagues,78 who 
showed that pain thresholds at multiple sites increased following knee joint replacement in 
people with osteoarthritis. At least for this pathological entity, maintenance of central 
hypersensitivity seems to be reliant on peripheral input. 
Alternative possible spinal cord mechanisms contributing to widespread pain are the 
opening of latent synaptic connections to WDR neurons with ongoing input, similar to the 
mechanism for referred pain, or the diffusion of substance P within the spinal cord dorsal 
horn, leading to a spread of activation of WDR neurons.186 At a supraspinal level, an 
imbalance in descending inhibition and facilitation may lead to a widespread increase in the 
excitability of dorsal horn neurons. For example, descending facilitation from the RVM 
would contribute to secondary hyperalgesia as it can impact at multiple spinal segments,56 
while blocking descending inhibition can increase the number of receptive fields of dorsal 
horn cells.186 Glial cell connections also may play a role given their extensive and rapid 
potential for activation. Any change in connectivity driven by persistent local inflammation 
may facilitate the sensitising effect of glia at other segmental locations. Finally, if the 
concentration of the prostaglandin forming enzyme COX-2 is elevated centrally following 
persistent inflammation, it will facilitate widespread production of prostaglandins in the 
dorsal horn, which will contribute to sensitisation of dorsal horn neurons at multiple levels. 
Of note, elevated levels of substance P, CGRP, and excitatory amino acids have been found 
in the cerebrospinal fluid of people with fibromyalgia187,188 and CRPS.189 
G. Sensory disturbances 
Impairments in other sensory modalities are frequently reported in long term pain 
conditions. For example, in people with CRPS, reduced tactile108-110 and touch thresholds,178 
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reduced awareness of limb position,190 dysgraphesia,135 body perception disturbances,135,190 
and neglect191 have been reported. Similar findings are evident in other chronic pain 
populations. Decreased kinaesthesia, altered body perception, reduced acuity, or 
dysgraphesia have been reported in chronic low back pain patients192-194 and people with 
repetitive strain injury,195 and hypoesthesia to multiple stimulus modalities is common in 
chronic whiplash.137 Additionally, telescoping, or the perception of shrinking and retraction 
of the phantom limb towards the residual limb, is often present in amputees196 but appears 
to be more prevalent in those with phantom limb pain than those without pain.102 The 
finding in two studies that abnormal sensory function in people with CRPS correlates with 
pain severity110,197 and that reduced joint position sense in whiplash is greater in those with 
higher levels of pain198 provides evidence of a relationship between these sensory 
disturbances and the nociceptive system.  
Alterations in somatosensory cortex representation are perhaps most likely to contribute to 
the reported features of reduced sensory acuity and impaired body perception disturbance. 
Tactile threshold is often normal in such populations192,194 even though the ability to use this 
information is impaired, and there is often no evidence of peripheral tissue damage or 
sensory deficits are present in areas remote from tissue damage. Therefore, impaired 
sensory function is likely to be of central origin. Some evidence for this is that two-point 
discrimination ability was shown to be related to the amount of primary somatosensory 
cortex reorganisation in people with CRPS.110 Reorganisation of the primary somatosensory 
cortex in phantom limb pain has also been associated with increased, non-painful stump 
sensations.131  
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An altered primary somatosensory cortex representation is also likely to increase difficulty 
in recognising body image. Studies involving people with chronic unilateral pain conditions 
have consistently indicated laterality recognition impairments compared to healthy 
individuals. Laterality testing involves assessing the person’s ability to identify the laterality, 
or side, of a visually presented body limb, most commonly a hand or foot. Such testing has 
shown that identification of the painful side is slower in populations with CRPS,199 phantom 
limb pain,200 and low back pain.201 This provides some evidence of a disordered working 
body schema in these populations and a reduced ability to correctly and rapidly identify 
body parts. Recent research in both experimental and chronic pain has revealed that visually 
manipulating body perception of the painful body part can provide pain relief,202-204 
although the hyper- and an-algesic effects of enlargement and shrinking were not consistent 
across these studies. Still, they provide further evidence of a strong link between body 
perception and pain. 
While cortical reorganisation may be large contributor to sensory disturbances, it is likely 
that spinal level plasticity initiated such alterations. Expanded and overlapping fields of WDR 
neurons that occur when sensitised are likely to alter the ascending input to the primary 
somatosensory cortex and drive the reorganisation occurring at this level.   
H. Impaired motor control 
Impairments in various aspects of motor control are routinely reported in chronic pain 
conditions. Indeed, the presence of motor signs and symptoms forms part of the diagnostic 
criteria for CRPS,205 with altered range of motion, tremor, weakness, dystonia, and 
discoordination commonly evident.206 In people with chronic low back pain, there have 
been reports of altered postural muscle activation113,207,208 and disturbances in 
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postural193,209 and balance210 tasks. Additionally, reduced muscle strength, impaired timing 
of muscle activation, and reduced range of motion are routinely present in people with 
whiplash.198 
Although motor impairments are common in a variety of chronic pain conditions, why they 
arise and how they are maintained is currently undetermined. A circular argument exists as 
to whether ongoing nociceptive input drives plasticity in the motor system and causes 
movement impairments, or impaired motor function contributes to activation of the 
nociceptive system and increases pain. Indeed, there have been many theories proposed211-
213 to account for the relationship between pain and motor dysfunction in people with 
painful musculoskeletal conditions, none of which completely explain symptoms in chronic 
neuropathic pain. It is likely that it is a highly complex relationship that may not be uniform 
among pain conditions. 
A large amount of evidence was provided in the preceding chapter of plasticity in motor 
cortex representation and excitability in chronic pain conditions, and it is likely that this 
central, motor cortical reorganisation is associated with movement impairments. An fMRI 
study showed that motor dysfunction in a reach-to-grasp task performed by people with 
CRPS was related to increased primary motor cortex and supplementary motor area 
activation during hand movement, with the amount of dysfunction correlated with 
activation in these regions.124 In a further study, the location and volume of trunk muscle 
representation in the primary motor cortex was associated with deficits in postural control 
in people with chronic back pain.113 The extent of motor reorganisation was correlated with 
the delayed onset of muscle activity during rapid arm movements. Thus, these studies 
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provide some evidence of a relationship between cortical motor plasticity and function 
impairments in people with long-term pain.  
One hypothesis is that this motor cortical reorganisation results in a difficulty integrating 
sensory information and motor output, and that this incongruence may indeed contribute 
to pain.214 It is known that acute experimental pain disrupts motor control,215 causes 
changes in spinal motoneuron216,217 and corticomotor excitability,216,218,219 and degrades 
proprioceptive information.220,221 In the long-term, such alterations, particularly in the 
quality and extent of afferent information, may cause more permanent changes in cortical 
motor representation and lead to sustained impairments in motor function. Plasticity in 
sensory regions may well contribute to motor impairment. Support for the importance of 
sensory information in chronic pain is provided by a study showing that tactile acuity was 
related to impaired motor control in people with low back pain.193 However, the cause and 
effect nature of this finding cannot be determined and the exact reasons for motor 
impairments in chronic pain populations remain challenging to determine. Perhaps the best 
insight will come from studies that have manipulated cortical motor excitability and 
examined the effect on pain and motor function. 
V. MANAGEMENT HARNESSING NEUROPLASTICITY 
While most of the preceding information has shown neuroplastic phenomena that may be 
causing or contributing to the chronic pain experience, it is also possible to take advantage 
of the highly plastic nature of the nervous system to identify appropriate treatment 
strategies and promote restoration of function and management of pain. The remainder of 
this article will focus on three techniques that aim to achieve this.  
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A. Sensory training  
Sensory discrimination training for chronic pain is not new, but developments in imaging 
technology have now provided evidence of neural plasticity in response to such 
interventions and have resulted in refined applications and wider acceptance of its use. 
Through focusing the patient’s attention on sensory information, sensory training aims to 
reverse reorganisation within the somatosensory cortex and reduce pain. Flor and 
colleagues222 were one of the first groups to specifically use sensory discrimination training 
for chronic pain. In this study, people with phantom limb pain were given electrical stimuli 
over their stump and were asked to discriminate the location and frequency of the stimuli. 
As well as improvements in the sensory task, there were marked significant reductions in 
pain and somatosensory cortex reorganisation. Notably, these changes in function, pain, 
and cortical representation were positively correlated. 
Sensory training has since been implemented in other chronic pain populations. In people 
with CRPS, it has been shown to reduce pain,108,223,224 improved sensory acuity,108,223,224 and 
improve function,223 while it was also effective in reducing pain and disability in people with 
chronic low back pain.225 Of note, Pleger and colleagues108 also reported an increased 
spatial representation in the primary and secondary somatosensory cortex in people with 
CRPS following training, suggesting a reversal of cortical reorganisation coincident with 
improved function and reduced pain. The provision of normal, contextual sensory 
information may therefore serve to undo the cortical reorganisation that has occurred and 
restore functional neural connections.  
It seems that focussed attention and functional use of the sensory input is integral to the 
success of sensory discrimination tasks. These factors are likely to prioritise non-noxious 
33 
 
afferent input to the spinal cord and supraspinal regions over any on-going nociceptive 
input. In support of this theory, there was no change in sensory performance or sensory 
cortical representation when CRPS patients undertook motor training without a sensory 
discrimination component.108 Additionally, Moseley223 reported that a sensory task involving 
discrimination of clinically relevant sensory stimuli was effective in reducing pain, but just 
receiving the equivalent sensory stimuli without the discrimination component was not 
effective. Visual attention toward the limb during training also appears to be an important 
factor for modulating the magnitude and duration of analgesia.224 
It is known that attention and task complexity enhance neural plasticity during motor 
learning226,227 and it is apparent that this also applies to neuroplastic changes in the sensory 
system during sensory training. Clinically, this would mean that progressively graded 
sensory discrimination training that requires the patient’s attention would be most 
beneficial. Functionally relevant stimuli should be used, potentially with multiple modalities, 
and the training should be individually adapted so that it constantly challenges the ability of 
the patient. Appropriate tasks include two-point spatial discrimination, identification of 
object textures, stimulus localisation identification, and graphethesia training.225 
B. Non-invasive brain stimulation 
Stimulation of the primary motor cortex for the treatment of chronic pain originated in the 
early 1990s using electrodes that were implanted within the cerebral cortex.228,229 Whilst 
effective pain relief was evident, the surgical procedure is highly invasive and comes with 
the associated risks of brain surgery. The development of non-invasive magnetic and 
electrical methods of brain stimulation saw these, far safer, techniques applied in people 
with chronic pain. Repetitive transcranial magnetic stimulation (rTMS) was initially trialled in 
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the 2000s and early results showed that a modest amount of pain relief could be 
achieved.230 More recent studies have made use of transcranial direct current stimulation 
(tDCS), which involves the delivery of current to the brain through electrodes placed over 
the scalp.  
Approximately 20 randomised controlled trials have examined the effect of non-invasive 
brain stimulation in neuropathic pain populations.231,232 The overwhelming majority of these 
have shown significant reductions in pain and often improvements in function or quality of 
life,233,234 clearly demonstrating the clinical potential of non-invasive brain stimulation. A 
recent meta-analysis revealed an effect size on pain of approximately 1.5 for tDCS applied to 
chronic pain populations,232 which is a clinically important effect. It is noteworthy that the 
majority of participants involved in these studies are drug-resistant patients who have not 
responded to other treatment methods.  
Both rTMS and tDCS can induce alterations in cortical excitability that outlast the period of 
stimulation.235-237 This lasting effect has important implications as it indicates the 
development of plasticity within intracortical structures. The excitatory effects of high 
frequency rTMS appear to arise through a long-term potentiation-like process subsequent 
to the development of cortical disinhibition.238-241 tDCS acts by modifying the 
transmembrane neuronal potential,242 influencing the level of resting excitability of 
individual neurons, and it is speculated that the lasting effects of stimulation are mediated 
via increased activation of NMDA channels.243 Importantly, the effects of motor cortex 
stimulation are not restricted to the area receiving stimulation; the function of distant sites 
also can be modulated through neuronal network connections.244  
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Exactly how motor cortex brain stimulation elicits its analgesic effects remains a mystery. It 
may act through direct connections from the primary motor cortex to the thalamus and 
primary somatosensory cortex. When applied to people with chronic pain, the analgesic 
effects of rTMS have been associated with normalisation of intracortical excitability,120,245 
which suggests that the mechanism of action may be related to changes in intracortical 
modulation. The high connectivity between the primary motor cortex, thalamus, and 
somatosensory cortex could mean that this modulation of intracortical motor circuits 
subsequently alters the processing of nociceptive input at these two locations. This 
mechanism would dictate that the sensory component of pain would primarily be 
influenced. There is, however, evidence that primary motor cortex stimulation has at least 
as great an effect on the affective aspect of pain.233,245 Alternatively, motor cortical 
polarisation could give rise to indirect activation of brainstem inhibitory pathways via 
connections from the motor cortex to other areas of the brain. Altered activation in the 
anterior cingulate cortex, insula, orbitofrontal regions, and brainstem has been documented 
following motor cortex stimulation,246-249 providing some evidence for this mechanism. It is 
also been shown that opioids meditate at least part of the analgesic response,250 and it is 
known that these brain areas have a high density of opioid receptors. Therefore, primary 
motor cortex stimulation may instigate opioid release that subsequently initiates activity in 
these limbic regions. In healthy individuals, direct stimulation over the dorsal lateral 
prefrontal cortex increases pain tolerance, suggesting that altered activation of this cortical 
area can modulate the affective experience of pain.250,251  
Both rTMS and tDCS are commonly used forms of brain stimulation, but tDCS is a clinically 
more practical and cheaper option. Indeed, programmable take-home versions of tDCS units 
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are now commercially available. The most frequently used stimulation parameters are 
anodal electrical or high frequency magnetic stimulation applied over the primary motor 
cortex representation. Optimal results appear to be seen with 5 consecutive days of 
stimulation. There is some evidence that this can provide significant pain relief for up to 3 
weeks233,234,252,253 but it is likely that the duration of this would be enhanced if further 
stimulation was provided. In support of this, Mhalla et al.245 demonstrated that the 
cumulative effect of a tapered rTMS protocol gave rise to pain relief for up to 6 months. 
Given the proposed mechanisms of action, some consideration of the location of application 
is warranted; stimulation over pre-frontal regions may be indicated for those who are not 
responsive to primary motor cortex stimulation. 
C. Mechanisms-based treatment approach 
As outlined in the previous sections, chronic pain may be associated with a multitude of 
neuroplastic changes at a number of different levels of the nervous system. Even within the 
same pain condition, there is a large degree of variability in the clinical presentation of pain-
related signs and symptoms.254-258 This is thought to reflect individual differences in the 
neuroplastic changes that drive the chronic pain experience for one person compared to 
another. Conversely, the type of pain treatment an individual receives is usually based on 
their diagnosed pain condition and the clinical experience of the treating health professional. 
In recent years, personalised treatment using a mechanisms-based approach has been 
advocated for chronic pain.259 Under this approach, symptom profiling and quantitative 
sensory testing are used in an attempt to delineate the specific neuroplastic changes 
underlying an individual’s pain experience and/or identify potential responders from a 
group of individuals prescribed the same treatment.  
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There are many examples that individuals who demonstrate marked allodynia and 
hyperalgesia with quantitative sensory testing may respond better to medications that 
reduce neuronal hyperexcitability. In people with neuropathic pain due to spinal cord injury, 
the systemic infusion of lamatrogine was more effective in those with brush allodynia and 
wind-up to punctuate mechanical input.260 Similarly, people with neuropathic pain who 
reported mechanical allodynia had a significantly greater reduction in ongoing pain with 
intravenous lidocaine infusion compared to those without allodynia.261 In individuals with 
HIV induced neuropathic pain, pregabalin did not significantly reduce pain compared to 
placebo;262 however, there was a reduction in pain in a subgroup with strong hyperalgesia 
to punctuate mechanical input. Finally, in a recent study of people with chronic pancreatic 
pain,263 pregabalin was found to be most effective in individuals with localised 
hypersensitivity to electrical stimulation over the upper abdomen when compared to a 
control site. Localised electrical hypersensitivity at baseline was able to predict the pain 
relieving effects of pregabalin with a classification accuracy of 84%.  
Further studies in people with painful diabetic neuropathy have shown that assessment of 
the nociceptive system can predict individual responses to specific analgesic medication. 
Campbell et al.264 categorised patients according to their response to capsaicin prior to 
undergoing treatment with topical clonidine gel or a placebo. It was hypothesised that a 
strong capsaicin response would indicate hypersensitive TRPV-1 (non-selective cation 
channel activated by noxious heat and chemical compounds) cutaneous nociceptors, a 
potential therapeutic target for clonidine. In people who failed to respond to capsaicin, 
clonidine was found to be ineffective compared to placebo. However, those who had a 
painful response to capsaicin showed a significant reduction in ongoing neuropathic pain 
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with clonidine compared to placebo. Yarnitsky et al.265 found that quantitative sensory 
testing of endogenous pain inhibitory pathways was able to predict the pain-relieving 
effects of duloxetine, a monoamine reuptake inhibitor. Individuals with less effective 
conditioned pain modulation at baseline had a greater reduction in pain, a response that is 
to be expected as conditioned pain modulation is largely determined by descending 
inhibition from brainstem monoamine pathways. In addition, the treatment-induced 
improvement in conditioned pain modulation was found to be correlated with medication 
efficacy.  
The observations above support the premise of a mechanisms-based approach to 
pharmacological management of chronic pain. By relating individual sensory profiles to 
specific neuroplastic changes that occur in the nociceptive system, it is hoped that 
individuals may receive more targeted interventions. In turn, this may achieve better 
therapeutic efficacy while limiting exposure to ineffective treatments and their associated 
side effects. While there is still a long way to go until such an approach becomes common 
practice, the evidence presented above suggests that this is a rational approach that holds 
considerable promise for the future treatment of chronic pain. 
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